Evidence map›Paper›PMID 38371381›Full record

ArticleBrain, behavior, & immunity - health2024

rTMS for post-covid-19 condition: A sham-controlled case series involving iTBS-300 and iTBS-600.

Mohammad Nazmus Sakib, Ashish Saragadam, Mariella C Santagata, Marie Jolicoeur-Becotte, Lena Kozyr, Amer M Burhan, Peter A Hall

Open access · goldAbstract read
In one paragraph

Article in Brain, behavior, & immunity - health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mohammad Nazmus SakibSchool of Public Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada.
Ashish SaragadamSchool of Public Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada.
Mariella C SantagataSchool of Public Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada.
Marie Jolicoeur-BecotteSchool of Public Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada.
Lena KozyrSchool of Public Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada.
Amer M BurhanOntario Shores Centre for Mental Health Sciences, Whitby, Canada.
Peter A HallSchool of Public Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada.
University of Waterloo · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-Covid-19 Condition (PCC) is a syndrome comprised of symptoms persisting 3 months or more beyond SARS-CoV-2 primary infection. It is typically characterized by fatigue, cognitive problems and psychiatric symptoms, as well as cardiac symptoms that contribute to exercise intolerance in many. Despite the high prevalence of PCC among those with a prior SARS-CoV-2 infection, there is currently no widely accepted rehabilitation strategy, and many conventional modalities are movement-based. Non-invasive brain stimulation methods such as repetitive transcranial magnetic stimulation (rTMS) may have some potential to alleviate the cognitive and affective symptoms of PCC without reliance on exercise. The purpose of the present study was to explore the feasibility and tolerability of using rTMS to treat symptoms of "brain fog" and affective disturbance among those living with PCC, using a case series design. We enrolled four individuals with PCC following a confirmed SARS-CoV-2 infection, at least 3 months after the resolution of the primary infection. Participants were randomized to 4 sessions of active and 2 sessions of sham intermittent theta-burst stimulation (iTBS); two intensities of iTBS were evaluated: iTBS-300 and iTBS-600. No adverse events occurred in active or sham stimulation; 2 participants reported tingling sensation on the scalp but no other tolerability issues. Trends in symptoms suggested improvements in cognitive interference, quality of life, and anxiety in the majority of participants. In summary, in this case series iTBS was well tolerated among 4 individuals with PCC; active stimulation was associated with positive trends in some primary symptom clusters as compared with sham stimulation. Future studies should examine the effects of iTBS on PCC symptoms in the context of experimental studies and randomized controlled trials.

Indexed as

Brain stimulationCase seriesCOVID-19Long-COVIDPCCrTMS

Identifiers

PMID38371381
PMCPMC10869745
OpenAlexW4391530002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.